

Laura Maria Fogliatto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5392/publications.pdf>

Version: 2024-02-01

33
papers

1,005
citations

840776

11
h-index

610901

24
g-index

33
all docs

33
docs citations

33
times ranked

1141
citing authors

#	ARTICLE	IF	CITATIONS
1	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	1.6	277
2	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	1.6	195
3	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	1.4	147
4	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 512-524.	10.7	144
5	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	7.2	72
6	DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application. <i>Bioanalysis</i> , 2015, 7, 2105-2117.	1.5	30
7	KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8005-8005.	1.6	24
8	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 50-56.	0.2	2
20	Economic Impact of Imatinib Mesylate Withdraw: An Option for Third World Countries?. <i>Blood</i> , 2015, 126, 5161-5161.	1.4	2
21	Results from a Hemato-Oncology Latin America Observational Registry (HOLA) Providing Real World Outcomes for the Treatment of Patients with NHL. <i>Blood</i> , 2016, 128, 5327-5327.	1.4	2
22	Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7545-7545.	1.6	1
23	Pregnancy during Treatment with Imatinib: A Case Report.. <i>Blood</i> , 2005, 106, 4851-4851.	1.4	1
24	BCR-ABL Fluctuation Analysis in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients with MR 4.5. <i>Blood</i> , 2015, 126, 5162-5162.	1.4	1
25	Imatinib Mesilate Versus Allogeneic Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia in First Chronic Phase - A Brazilian Point of View.. <i>Blood</i> , 2007, 110, 1096-1096.	1.4	0
26	Warning As Defiened By European Leukemia Net 2013 (ELN 2013) In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Corresponds To Warning In The Clinical Practice?. <i>Blood</i> , 2013, 122, 5176-5176.	1.4	0
27	The Impact of Early Molecular Response in Event Free Survival in Patients with Chronic Myeloid Leukemia Treated with Imatinib. <i>Blood</i> , 2014, 124, 5536-5536.	1.4	0
28	TKI Treatment Discontinuation: How Many Patients Could Stop Tyrosine Kinase Treatment According to Discontinuation Trials Criteria? Incidence and Prognostic Impact of Deep Molecular Response in a Cohort of Chronic Myeloid Leukemia Patients of South Brazil's Hematology Centers. <i>Blood</i> , 2014, 124, 5542-5542.	1.4	0
29	The Assessment of the European Leukemianet Criteria for Clinicohematologic Resistance and Intolerance to Hydroxyurea in Polycythemia Vera Is Not Easily Applicable in Daily Practice. <i>Blood</i> , 2014, 124, 5550-5550.	1.4	0
30	Pharmacogenetic Markers of Treatment Response of Imatinib Mesylate in Chronic Myeloid Leukemia Brazilian Patients. <i>Blood</i> , 2016, 128, 5458-5458.	1.4	0
31	Efficacy and time to next treatment following lenalidomide/rituximab (R ²) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7514-7514.	1.6	0
32	COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience. <i>Blood</i> , 2020, 136, 48-49.	1.4	0
33	Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL. <i>Blood</i> , 2020, 136, 2-2.	1.4	0